Compare IONQ Inc (IONQ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Twist Bioscience Corp — how do they compare? IONQ Inc trades at $39.87 (market cap $15.98B), while Twist Bioscience Corp trades at $160.9 (market cap $10.08B). The key difference: IONQ Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Twist Bioscience Corp for 27 Days on average.
| IONQ | TWST | |
|---|---|---|
Market Cap | $15.98B | $10.08B |
Volume | 22,848,240 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $82.09 | $205.00 |
52-Week Low | $26.59 | $25.45 |
Typical Hold Time | 33 Days | 27 Days |
Enterprise Value | $13.92B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.63, down 4.14% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported revenue of $130.02M in 2025 but posted a net loss of $510.38M, reflecting negative profit margins of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss after two consecutive beats. Analyst sentiment remains divided with a 50/50 buy/hold split but a consensus price target of $62.75 suggesting significant upside potential from current levels.
The outlook for IONQ hinges on scaling quantum computing technology to justify its premium valuation (P/S 54.74). While strong revenue growth projections and strategic partnerships offer long-term potential, investors face substantial risks from persistent losses, cash burn, and intense competition in the emerging quantum computing sector.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
